Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 1;34(8):962-966.
doi: 10.1097/CAD.0000000000001497. Epub 2023 Jan 4.

Major pathological remissions in a patient with stage IIIA nonsmall cell lung cancer after neoadjuvant tislelizumab combined with chemotherapy: a case report and literature review

Lu-Zhen Li  1 , Si-Hong Lin, Le-Xia Wu, Ting Chen, Juan-Na Zhuang, Hui-Qin Lai, Zhan-Peng Liang, Wan-Shan Zhu, Wen-Xia Li, Lu Tang, Hua-Tang Zhang, Can-Tu Fang
Affiliations
Review

Major pathological remissions in a patient with stage IIIA nonsmall cell lung cancer after neoadjuvant tislelizumab combined with chemotherapy: a case report and literature review

Lu-Zhen Li et al. Anticancer Drugs. .

Abstract

Introduction: Currently, there are few reports of patients with locally advanced lung cancer achieving a clinical complete response by medical treatment. Preoperative neoadjuvant immunotherapy combined with chemotherapy is an option for patients with unresectable, locally advanced nonsmall cell lung cancer (NSCLC) which is of great potential, and may change traditional treatment paradigms. There are relatively few large-scale, high-quality randomized-controlled trials yet, and limitations such as short postoperative follow-up period and immature disease-free survival and overall survival data still persist. Thus, evidence-based medical evidence is urgently needed. It is worthy to explore the further treatment of patients who achieved complete response after initial treatment, though lacking of evidence by now.

Case presentation: We report a stage IIIA lung squamous cell carcinoma case who achieved a major pathologic remission after neoadjuvant treatment with tislelizumab and chemotherapy.

Conclusion: Our case study contributes to the existing evidence on the feasibility, efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced unresectable NSCLC.

PubMed Disclaimer

References

    1. Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E, et al. A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. Front Oncol 2021; 11:744956.
    1. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386:1973–1985.
    1. Zhang C, Jiang W, Li G, Li J, Kang Y, Yu X, et al. Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report. Ann Palliat Med 2021; 10:3510–3517.
    1. Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R. Complete pathologic response when adding pembrolizumab to neoadjuvant chemotherapy in stage IIIA non-small-cell lung cancer. J Oncol Pract 2018;14:569–571 [Epub 2018 Jul 25].
    1. Liu Y, Gao Z, Zhang C, Liu X, Liu Z, Lin X, et al. Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report. Anticancer Drugs 2022; 33:e784–e788.

MeSH terms